Enhertu Secures EU Approval for Post-Neoadjuvant Breast Cancer Treatment
Event summary
- The European Medicines Agency (EMA) validated a Type II Variation application for ENHERTU (trastuzumab deruxtecan) as a monotherapy for HER2 positive early breast cancer patients.
- The validation follows data from the DESTINY-Breast05 Phase 3 trial, presented at ESMO 2025 and published in The New England Journal of Medicine.
- DESTINY-Breast05 demonstrated a statistically significant improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1).
- ENHERTU is jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
- Additional regulatory submissions are underway in the EU for ENHERTU in combination with pertuzumab and for other cancer types.
The big picture
The approval represents a significant advancement in treating HER2-positive early breast cancer, a market segment with a substantial unmet need given the high recurrence rates. This validation underscores the growing trend towards targeted therapies and antibody-drug conjugates (ADCs) in oncology, a market estimated to be worth tens of billions globally. The joint venture between Daiichi Sankyo and AstraZeneca highlights the increasing complexity and cost of drug development, necessitating partnerships to share risk and resources.
What we're watching
- Regulatory Scrutiny
- The EMA’s review process will be critical; any unexpected delays or requests for additional data could impact ENHERTU’s market entry and Daiichi Sankyo and AstraZeneca’s revenue projections.
- Competitive Landscape
- The success of ENHERTU in this post-neoadjuvant setting will likely intensify competition with other HER2-targeted therapies, potentially impacting pricing and market share.
- Clinical Expansion
- The pace at which Daiichi Sankyo and AstraZeneca advance ENHERTU’s approval for other indications (combination therapies, other cancer types) will determine the drug’s overall commercial potential.
Related topics